Vanguard Global Advisers’s Oric Pharmaceuticals ORIC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$473K Buy
35,130
+6,833
+24% +$85.1K ﹤0.01% 2115
2026
Q2
$306K Sell
28,297
-11,558
-29% -$105K ﹤0.01% 2319
2026
Q1
$505K Buy
+39,855
New +$452K ﹤0.01% 2040

Other funds holding ORIC

Vanguard Global Advisers's ORIC Position: Q3 2026 in Review

Vanguard Global Advisers increased its Oric Pharmaceuticals (ORIC) stake by 24% in Q3 2026, buying an estimated $85.1K and bringing the position to 35,130 shares worth $473K. The position accounts for ﹤0.01% of the portfolio, ranked #2115.

Vanguard Global Advisers first reported a position in ORIC in Q1 2026 and has held it in 3 quarters since. The position peaked at $505K in Q1 2026. 203 funds tracked by Wall St. Rank hold ORIC as of Q3 2026.

  • Vanguard Global Advisers held 35,130 shares of Oric Pharmaceuticals worth $473K as of Q3 2026.
  • Vanguard Global Advisers bought 6,833 Oric Pharmaceuticals shares in Q3 2026, an estimated $85.1K.
  • Oric Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2115 holding.
  • Vanguard Global Advisers first reported a position in Oric Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Oric Pharmaceuticals position peaked at $505K in Q1 2026.
  • 203 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.